Member Info for Bermudashorts

AB124/EE

Interesting, a significant holder perhaps but not so significant as to hold a notifiable interest and I suspect not an institution who surely would have sold in a more sophisticated manner.

Correction - 'Keytruda patients' and not 'Keytruda patient's'

BOJO - the cost of both Pembrolizumab and Nivolumab should be covered by the NHS as standard of care treatment and so cost shouldn't be a factor.

Johnny - as I understand it, both Pembrolizumab (Keytruda) and Nivolumab (Opdivo) are approved treatments in advanced H&N cancer, although I think Keytruda patient's must have tumours with a minimum level of PD-LI expression to qualify. It's down to the consultant to select which one he thinks is most appropriate for the patient and it may simply be coincidence that all 3 patients in cohort 4 were prescribed Opdivo.

Are you sure that Scancell have ditched Keytruda? The RNS says that the cohorts are being expanded which could be taken to mean that the original entry criteria still apply.

Cleanerworld,

Yes, you're quite right, it was a knee-jerk response to your scepticism with no explanation. Nevertheless, as you say it was a waspish response for which I apologise.

It would be good if you could answer my question though - why precisely are you sceptical?

Cleanerworld,

Re. point no. 7 from your earlier post.

I'm sorry to hear that you're sceptical about Crumbs and my posts - any specific reason/errors/mistakes or are they just not positive enough?

Yep an impressive update, particularly in the current enviroment.

Have been having another look at Redx and came across this excellent recent interview with Redx's CEO Lisa Anson.

Regardless of whether you're invested in Redx or not it's well worth a listen if you invest in the AIM life sciences sector as she gives a great insight into the reality of running a life sciences company in the UK today. Her comments regarding the funding challenges, the lack of specialsit UK funds as well as the drawbacks of running late stage trials in the UK and drug pricing are particularly interesting.

https://podcasts.apple.com/gb/podcast/lisa-anson-ceo-of-redx-pharma-how-to-make-the/id1692739845?i=1000620867814

Falsedawn,

Thanks for the reply and good to hear from you.

You may be right, but I had thought that shares issued from a block listing were exempt from the usual disclosure requirements and companies only needed to notify the market every 6 months of any increase in the issued share capital if related to the block listing. As you say, no matter as we'll find out soon enough. Think the block listing report due in August is for the convertible loans and the RG options one is due in October, but again I could be wrong.

Square10

As Richard is no longer connected to Scancell, there's no need to issue an RNS if he exercises his options. The only way we'll find out is when Scancell issue their next block listing six monthly report.

Crumbs,

I'm not sure I entirely agree regarding LD. Since first investing in Scancell we've had Richard Goodfellow, Cliff Holloway, David Evans and John Chiplin all of whom seemed confident of a deal but didn't actually get that signature on the dotted line. The only one who has actually managed to close a deal is Lindy Durrant with the Genmab agreement. Not only that it was preclinical without even a defined product. So she has demonstrated that she can negotiate deals and is prepared to let go of the IP and I think she will happily license any of the ImmunoBody or Moditope IP when she can.

Johnny

Thanks for that and makes sense.

I'm sure all will become clear as and when Scancell present their findings in detail at scientific conferences or via peer reviewed journals.

Crumbs,

The first evaluation point is imaging at 8 weeks, so as the original 4 non-ovarian patients were receiving the full dose back in February, they must have reached the evaluation point. We simply don't know about the next 4, but you'd have thought if they had yet to be evaluated then Scancell would have said so in the RNS.

Also in the RNS of 21st Feb we were told that they had dosed 18 ovarian cancer patients but in the last update it was 16 which ties in with the ASCO poster - not sure what has happened to the additional 2 patients or whether that figure was an error.

Crumbs - all I know is that some people blame coral reefs for the hundreds of shipwrecks surrounding the shores of Bermuda but it's very easy to convince others that mysterious forces are at play. I'd go along with the straightforward simple explanation - coral is very sharp. Either way it makes for great diving.

Crumbs,

From memory CI's are approved in TNBC but in combination with chemo which of course would exclude a patient from the Modi-1 trial - so that may be it.

Crumbs,

See slide 12 from AGM presentaion, just a few months ago. The intention was certainly there and now we're not sure and we don't know why. To be honest I'm more interested in the neoadjuvant study and what's happening there as well as Modi2. As you say, it could be that they are streamlining to conserve cash and if that's the case then Lindy and her team will have chosen to develop the parts of the pipeline with the best/quickest chance of success and we obviously have to accept that.

Nevertheless, we have just received initial results from the first fully recruited arm of the Modi-1 trial. This could/should (?) have been a major inflection point, but actually the message is 'still encouraging but we now need further studies'. They can't even apply to run those studies until they have data from the combination arms of the current trial and they don't yet have approval to open those arms to recruitment.

As you can tell, I'm a little disappointed and have reduced my holding. Timelines have potentially extended yet again and it seems that Scancell's strategy going forwards is to carry out phase III registration studies and apply for marketing approval themselves. A massive commitment and I hope they are able to partner beforehand.

I will keep a much smaller core holding and can honestly say that I would be more than delighted to have called this wrong and to find myself having to buy back the stock at a higher price if good news lands.

https://scancell.co.uk/Data/Sites/1/media/docspres/agm-presentationnovember-2022_final.pdf

https://scancell.co.uk/Data/Sites/1/media/docspres/agm-presentationnovember-2022_final.pdf

Crumbs/Violindog,

The original intention (according to the published trial design) was to expand the combination arm of the study to recruit 21 patients for each tumour type - head and neck, renal and breast cancer. The intention to run a combination cohort for TNBC was confirmed in the AGM presentation so this has come directly from Scancell and CI's have been approved in TNBC (albeit in combo as with renal cancer I think) However according to the RNS yesterday they are only expanding in head and neck and renal cancer patients. There is no mention of a combination arm in breast cancer and no explanation as to why. Nor is there any mention of the neoadjuvant study in head and neck. It may be the RNS was incorrect and they simply forgot to mention TNBC (highly unlikely), it could be that due to SOC issues with the CI that it would be difficult to recruit or they may intend to run these arms at a later date - who knows? ...........and I think that's the point, we don't know hence my comment last night about raising more questions than answers.

Matt,

Agreed - as often is the case, the RNS seems to raise as many questions as it answers. Very pleased to see that Lindy possibly will be doing an Investor Meet presentation and hopefully we'll be given the chance to ask some of those questions.

Green453,

In answer to your 8.06 - yes Nivolumab is Bristol Myer's PD-1 inhibitor Opdivo. Both Keytruda and Nivolumab are approved as standard of care therapies for advanced melanoma and so both are included as combination CI's for the SCIB1 trial. Otherwise recruitment would be restricted to those patients being prescribed Keytruda. I think it's as simple as that.

Interesting that according to the RNS, the combination study is being expanded in head and neck and renal cancers but no mention of TNBC. Perhaps due to labelling for checkpoint inhibitors in this type of cancer or maybe it will be added later?

Below is a link to a peer reviewed research paper from scientists at the FDA which was published yesterday. The paper reviews the most promising glycan targeting immunotherapies and Scancell's research featuring the SC129 glycan mAb is cited in the paper. This is the mAb that has been licensed by Genmab and I have also added a link to the cited paper.

The review is long and probably beyond most of us here with the exception of Burble but well worth at least a read of the intro and conclusion. This in particular:-

'As the glycoimmunology continues to evolve, our better understanding of the process, presentation of the carbohydrate antigens on immune cells, and their responses to the TACAs (especially the engagement of T cells) will lead to better designs of TACA immunogens which will not only elicit more specific mAbs with higher affinity for applications of mAb therapy and CART therapy, but also develop more effective anti-cancer glyco-vaccines. Thus, the TACA-targeted immunotherapy is expected to evolve as one of the effective anti-cancer regimens in the treatment of solid tumors in a new era.'

Finally, in light of discussions yesterday, worth noting that the SC129 research from Scancell was actually government funded via a grant from the Medical Research Council.

https://www.mdpi.com/2072-6694/15/14/3536#B179-cancers-15-03536

https://aacrjournals.org/mct/article/19/3/790/92797/Monoclonal-Antibody-Targeting-Sialyl-di-Lewisa

'

TF

Well as a Scancell shareholder I'd agree with you although of course Scancell has had support over the years. The discovery of much of its IP funded by the state and it has received millions of £s in grant funding and R&D tax credits. So, whilst we'd be happy with extra support for Scancell, as taxpayers would we be happy with the same level of support for other bios? I'm not so sure - the cash has to come from somewhere.